Page last updated: 2024-10-31

mitoxantrone and Purpura, Thrombotic Thrombocytopenic

mitoxantrone has been researched along with Purpura, Thrombotic Thrombocytopenic in 1 studies

Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.

Purpura, Thrombotic Thrombocytopenic: An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE. Mutations in the ADAMTS13 PROTEIN gene have been identified in familial cases.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Johnson, PR1
Yin, JA1
Drayson, MT1

Other Studies

1 other study available for mitoxantrone and Purpura, Thrombotic Thrombocytopenic

ArticleYear
Thrombotic thrombocytopenic purpura following allogeneic bone marrow transplantation.
    Bone marrow transplantation, 1991, Volume: 7, Issue:4

    Topics: Adult; Bone Marrow Transplantation; Cyclophosphamide; Epilepsy, Tonic-Clonic; Fever; Graft vs Host D

1991